| abstract |
Vaccine for use in blocking the reactivation of tuberculosis in individuals with latent infection with M. tuberculosis, which comprises an antigen that is constitutively expressed during infection with M. tuberculosis or a nucleic acid encoding said antigen, in which The antigen, belonging to the ESX-1 excretion system, is selected from the group consisting of: i) ESAT6, CFP10, Rv3614c, Rv3615c, EspR, Rv3868, Rv3869, Rv3870, Rv3871, Rv3872, Rv3873, Rv3876, Rv3877, Rv3878, Rv3879c, Rv3880c, Rv3881c, Rv3882c, Rv3883c and Rv3865, ii) an immunogenic part comprising an epitope of a B cell or T cell of any of the sequences in (i), and iii) an amino acid sequence analog having a sequence identity of at least 90% with respect to any of the sequences in (i) or (ii) and being simultaneously immunogenic by blocking the reactivation of latent tuberculosis infection when administered as therapeutic vaccine |